The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Open accessAbstract
BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more. RESULTS: Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy. CONCLUSIONS: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab, a PD-1 inhibitor, in combination with ipilimumab, a CTLA-4 inhibitor, has shown favourable efficacy outcomes and manageable safety profiles across multiple tumour types.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [39]
In the citing paper
“First-line nivolumab + ipilimumab treatment also produced longer OS than chemotherapy in patients with advanced NSCLC10.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“First-line nivolumab + ipilimumab resulted in a longer duration of OS than chemotherapy in patients with metastatic NSCLC, irrespective of the PD-L1 expression10,28.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“most notably the combination of pembrolizumab and axitinib (an inhibitor of vascular growth factor inhibitor) in renal cell carcinoma.15”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [15]
In the citing paper
“Until now, the FDA has approved the ipilimumab plus nivolumab for melanoma, RCC, MSI-H/dMMR colorectal cancer, HCC, PD-L1 positive NSCLC, and malignant pleural mesothelioma (Table 5) [132–138].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
In the citing paper
“Moreover, the data of CheckMate-214, CheckMate-227, and CheckMate-743 indicated the superior efficacy of ipilimumab plus nivolumab over the standard targeted therapy or chemotherapy [135–137].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Self-citationFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,003
Passiglia, F., Galvano, A., Gristina, V., Barraco, N., Castiglia, M., Perez, A., Mantia, M. L., Russo, A. D., & Bazan, V. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-52 · Cited by 33
Current cancer therapies and their influence on glucose control
Yim, C., Mansell, K. D., Hussein, N., & Arnason, T. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.1010 · Cited by 34
Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 33
Shiraishi, Y., Hakozaki, T., Nomura, S., Kataoka, T., Tanaka, K., Miura, S., Sekino, Y., Ando, M., Horinouchi, H., Ohe, Y., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.10.012 · Cited by 32
Goldman, J. W., Piha-Paul, S. A., Curti, B. D., Pedersen, K. S., Bauer, T. M., Groenland, S. L., Carvajal, R. D., Chhaya, V., Kirby, G., McGlinchey, K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3016 · Cited by 33
Immune-based combination therapy for esophageal cancer
Wang, H., Xu, Y., Zuo, F., Liu, J., & Yang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020290 · Cited by 33
Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer
Sobhani, N., Tardiel-Cyril, D. R., Chai, D., Generali, D., Li, J., Vazquez‐Perez, J., Lim, J. M., Morris, R. M., Bullock, Z. N., Davtyan, A., et al. (2024) · BJC Reports · doi:10.1038/s44276-023-00035-5 · Cited by 33
Vitale, E., Rizzo, A., Maistrello, L., Cauli, O., Mollica, V., Monteiro, F. S. M., Soares, A., Massari, F., & Santoni, M. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.10.031 · Cited by 33
Principles of Immunotherapy in Non-Small Cell Lung Cancer
Hsu, M. L., & Naidoo, J. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.009 · Cited by 33
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
Duchemann, B., Remón, J., Naigeon, M., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., Desnoyer, A., Besse, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-839 · Cited by 33
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
Russano, M., Cava, G. L., Cortellini, A., Citarella, F., Galletti, A., Fazio, G. R. D., Santo, V., Brunetti, L., Vendittelli, A., Fioroni, I., et al. (2023) · Current Oncology · doi:10.3390/curroncol30020181 · Cited by 34
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
Nikoo, M., Rabiee, F., Mohebbi, H., Eghbalifard, N., Rajabi, H., Yazdani, Y., Sakhaei, D., Khosravifarsani, M., & Akhavan‐Sigari, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109881 · Cited by 33
CheckMate-067: Raising the Bar for the Next Decade in Oncology
Weiss, S. A., & Kluger, H. M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02549 · Cited by 32
Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Younis, A., & Gribben, J. G. (2024) · Immuno · doi:10.3390/immuno4030013 · Cited by 34
Cortellini, A., Brunetti, L., Fazio, G. R. D., Garbo, E., Pinato, D. J., Naidoo, J., Katz, A., Loza, M., Neal, J. W., Genova, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010674 · Cited by 33
Self-citationThymic health and immunotherapy outcomes in patients with cancer
Bernatz, S., Prudente, V., Pai, S., Kjær, A., Federico, A. D., Rowan, A., Veeriah, S., Dyrskjøt, L., Nürnberg, L., Alessi, J. V., et al. (2026) · Nature · doi:10.1038/s41586-026-10243-x · Cited by 42
Cancer immunotherapy: Current applications and challenges
Sun, J., & Lu, X. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.03.024 · Cited by 30
Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
Olofsson, G. H., Jensen, A. W. P., Idorn, M., & Straten, P. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113816 · Cited by 34
Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
Park, R., Eshrat, F., Al‐Jumayli, M., Saeed, A., & Saeed, A. (2020) · Vaccines · doi:10.3390/vaccines8030447 · Cited by 31
Pecora, A. L., Halpern, S. L., Weber, M. S., Paleoudis, E. G., Panush, D., Patterson, F. R., & Toretsky, J. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000332 · Cited by 33
Pathak, R., Lopes, G. D. L., Jr., Yu, H., Aryal, M. R., Ji, W., Frumento, K. S., Wallis, C. J. D., Klaassen, Z. W. A., Park, H. S.-M., & Goldberg, S. B. (2020) · Cancer · doi:10.1002/cncr.33269 · Cited by 30
Kao, C., Powers, E., Wu, Y. S., Datto, M., Green, M. F., Strickler, J. H., Ready, N., Zhang, T., & Clarke, J. M. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.03.017 · Cited by 30
Albrecht, T., Brinkmann, F., Albrecht, M. C., Lonsdorf, A. S., Mehrabi, A., Hoffmann, K., Kulu, Y., Charbel, A., Vogel, M. N., Rupp, C., et al. (2021) · Cancers · doi:10.3390/cancers13071682 · Cited by 31
Krishnan, M., Kasinath, P., High, R., Yu, F., & Teply, B. A. (2021) · JCO Oncology Practice · doi:10.1200/op.20.01055 · Cited by 31
Xu, X., Wang, D., Chen, W., Li, N., Suwiński, R., Rossi, A., Rosell, R., Zhong, J., & Fan, Y. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-899 · Cited by 30
Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
Gemelli, M. T., Noonan, D. M., Carlini, V., Pelosi, G., Barberis, M. C. P., Ricotta, R., & Albini, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.886440 · Cited by 32
Güven, D. C., Şahin, T. K., Erul, E., Çakır, İ. Y., Üçgül, E., Yıldırım, H. Ç., Aktepe, O. H., Erman, M., Kılıçkap, S., Aksoy, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154523 · Cited by 31
Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
Yu, L., Sun, M., Zhang, Q., Zhou, Q., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982026 · Cited by 32
Rebuzzi, S. E., Prelaj, A., Friedlaender, A., Cortellini, A., Addeo, A., Genova, C., Naqash, A. R., Auclin, É., Mezquita, L., & Banna, G. L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103806 · Cited by 34
O'Byrne, K. J., Popoff, E., Badin, F. B., Lee, A., Yuan, Y., Lozano‐Ortega, G., Eccles, L. J., Varol, N., Waser, N. A., Penrod, J. R., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.01.006 · Cited by 31
Self-citationReck, M., Popat, S., Grohé, C., Corral, J., Novello, S., Gottfried, M., Brueckl, W. M., Radonjic, D., Kaiser, R., & Heymach, J. V. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.009 · Cited by 32
Self-citationGatto, L., Nunno, V. D., Tosoni, A., Bartolini, S., Ranieri, L., & Franceschi, E. (2023) · Cancers · doi:10.3390/cancers15123251 · Cited by 31
Management of Brain Metastases
Collier, E. F., Chiang, V., & Goldberg, S. B. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_6 · Cited by 32
[Pharmacokinetics and metabolism of trazodone in man (author's transl)].
Jauch, R., Kopitar, Z., Prox, A., & Zimmer, A. (1976) · PubMed · Cited by 31
Shaikh, F. Y., Gills, J. J., Mohammad, F., White, J. R., Stevens, C. M., Ding, H., Fu, J., Tam, A., Blosser, R. L., Domingue, J. C., et al. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-022-03169-6 · Cited by 30
Role of PD-L1 assessment in advanced NSCLC: does it still matter?
Rizzo, A., Dall’Olio, F. G., Altimari, A., Giunchi, F., & Ardizzoni, A. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001118 · Cited by 30
Iwasa, S., Koyama, T., Nishino, M., Kondo, S., Sudo, K., Yonemori, K., Yoshida, T., Tamura, K., Shimizu, T., Fujiwara, Y., et al. (2022) · Cancer Science · doi:10.1111/cas.15574 · Cited by 31
The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
Conway, J. W., Braden, J., Wilmott, J. S., Scolyer, R. A., Long, G. V., & da Silva, I. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030147 · Cited by 32
Ahmed, J., Das, B., Shin, S. J., & Chen, A. P. (2023) · Cancers · doi:10.3390/cancers15245841 · Cited by 36
Cole, M., Anastasiou, P., Lee, C., Yu, X., de Castro, A., Roelink, J., Moore, C., Mugarza, E., Jones, M. L., Valand, K., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl6464 · Cited by 33
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
Han, J., Tian, K., Yang, J., & Gong, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.011 · Cited by 30
You, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 31
Saxena, P., Singh, P. K., Malik, P. S., & Singh, N. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00768-2 · Cited by 30
Gamat, M., Jeon, D., Johnson, L. E., Moseman, J. E., Muralidhar, A., Potluri, H. K., Rastogi, I., Wargowski, E., Zahm, C. D., & McNeel, D. G. (2020) · Cancers · doi:10.3390/cancers12102831 · Cited by 31
Novaes, J. A. M. D. O., Hirz, T., Guijarro, I., Nilsson, M. B., Pisegna, M. A., Poteete, A., Barsoumian, H. B., Fradette, J. J., Chen, L. N., Gibbons, D. L., et al. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0418 · Cited by 30
Suwanvecho, S., Suwanrusme, H., Jirakulaporn, T., Issarachai, S. S., Taechakraichana, N., Lungchukiet, P., Decha, W., Boonpakdee, W., Thanakarn, N., Wongrattananon, P., et al. (2021) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaa334 · Cited by 34
The evolving landscape of immunotherapy in solid tumors
Keilson, J. M., Knochelmann, H. M., Paulos, C. M., Kudchadkar, R. R., & Lowe, M. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26416 · Cited by 31
Zhai, C., Zhang, X., Ren, L., You, L., Pan, Q., Pan, H., & Han, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.619010 · Cited by 29
Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
Tsang, J., Wong, J. S. L., Kwok, G. W., Li, B. C. W., Leung, R. C.-Y., Chiu, J. W. Y., Cheung, T. T., & Yau, T. C. C. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1899808 · Cited by 29
The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma
Yuan, H., Liu, J., & Zhang, J. (2021) · Molecules · doi:10.3390/molecules26051392 · Cited by 30
Nie, R., Chen, G.-M., Wang, Y., Zhou, J., Duan, J., Zhou, Z., & Yuan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.538174 · Cited by 31
Wang, B., Guo, H., Xu, H., Yu, H., Chen, Y., & Zhao, G. (2021) · Cells · doi:10.3390/cells10102620 · Cited by 29
PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
Lee, M. K. C., Grimmond, S. M., McArthur, G. A., & Sheppard, K. E. (2021) · Cancers · doi:10.3390/cancers13205136 · Cited by 30
Liu, W., Quan, B., Lu, S., Tang, B., Li, M., Chen, R., Ren, Z., & Yin, X. H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771045 · Cited by 30
Barth, D. A., Stanzer, S., Terzic, J. A., Bauernhofer, T., Absenger, G., Posch, F., Lipp, R., Halm, M., Szkandera, J., Balić, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4675 · Cited by 29
Lau, D., Khare, S., Stein, M. M., Jain, P., Gao, Y., BenTaieb, A., Rand, T., Salahudeen, A. A., & Khan, A. A. (2022) · Nature Communications · doi:10.1038/s41467-022-31769-4 · Cited by 32
Liu, S., Dou, L., Wang, K., Shi, Z., Wang, R., Zhu, X., Song, Z., & Li, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.899966 · Cited by 30
de Ruiter, B.-M., van Hattum, J. W., Lipman, D., de Reijke, T. M., van Moorselaar, R. J. A., van Gennep, E. J., Piet, A. H. M., Donker, M., van der Hulle, T., Voortman, J., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.07.009 · Cited by 31
Guezour, N., Soussi, G., Brosseau, S., Abbar, B., Naltet, C., Vauchier, C., Poté, N., Hachon, L., Namour, C., Khalil, A., et al. (2022) · Cancers · doi:10.3390/cancers14163878 · Cited by 30
Paz-Ares, L. G., Ciuleanu, T., Płużański, A., Lee, J., Gainor, J. F., Otterson, G. A., Audigier-Valette, C., Ready, N., Schenker, M., Linardou, H., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.08.014 · Cited by 31
Self-citationCirculating Biomarkers for Prediction of Immunotherapy Response in NSCLC
Goh, K. Y., Cheng, T. Y. D., Tham, S. C., & Lim, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020508 · Cited by 31
Altan, M., Wang, Y., Song, J., Welsh, J. W., Tang, C. Z., Guha‐Thakurta, N., Blumenschein, G. R., Carter, B. W., Wefel, J. S., Ghia, A. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006871 · Cited by 31
An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma
Chen, H., Lin, R., Lin, W., Chen, Q., Ye, D., Li, J., Feng, J., Cheng, W., Zhang, M., & Qi, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-12301-6 · Cited by 28
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., & Roviello, G. (2022) · Cancers · doi:10.3390/cancers14246145 · Cited by 29
Qu, F., Zhou, Y., & Wu, S. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02482-w · Cited by 30
Morita, A., Ichihara, E., Inoue, K., Fujiwara, K., Yokoyama, T., Harada, D., Ando, C., Kano, H., Oda, N., Tamura, T., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34842 · Cited by 29
Xue, G., Li, X., Kalim, M., Fang, J., Jiang, Z., Zheng, N., Wang, Z., Li, X., Abdelrahim, M., He, Z., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.001 · Cited by 30
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
Xiang, M., Li, H., Zhan, Y., Ma, D., Gao, Q., & Fang, Y. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01987-z · Cited by 29
Peters, S., Paz-Ares, L. G., Reck, M., Carbone, D. P., Brahmer, J. R., Borghaei, H., Lü, S., O'Byrne, K. J., John, T., Ciuleanu, T., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1439 · Cited by 32
Self-citationHuman immune system: Exploring diversity across individuals and populations
Nguyen, K. H. H., Le, N. V., Nguyen, P., Nguyen, H. H. T., Hoang, D. M., & Huynh, C. D. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41836 · Cited by 37
Sesma, A., Pardo, J., Cruellas, M., Gálvez, E. M., Ruiz, M. G., Isla, D., Martínez‐Lostao, L., Ocáriz, M., Paño, J. R., Quílez, E., et al. (2020) · Cancers · doi:10.3390/cancers12102974 · Cited by 28
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
Gavralidis, A., & Gainor, J. F. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000491 · Cited by 28
Fanciulli, G., Molfetta, S. D., Dotto, A., Florio, T., Feola, T., Rubino, M., de Cicco, F., Colao, A., Faggiano, A., & NIKE Group (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010088 · Cited by 30
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
Li, W., Peng, A., Wu, H., Quan, Y., Li, Y., Lu, L., & Cui, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.601497 · Cited by 29
Li, B., Jiang, C., Pang, L., Zou, B., Ding, M., Sun, X., Yu, J., & Wang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627197 · Cited by 30
Xiao, G., Liu, Z., Gao, X., Wang, H., Peng, H., Li, J., Yang, L., Duan, H., & Zhou, R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0262 · Cited by 32
Karschnia, P., Rhun, É. L., Vogelbaum, M. A., van den Bent, M. J., Grau, S. J., Preusser, M., Soffietti, R., von Baumgarten, L., Westphal, M., Weller, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.032 · Cited by 30
Recent advance in nanomaterials for cancer immunotherapy
Hou, Y., Liu, Y., Tang, C., Tan, Y., Zheng, X., Deng, Y., He, N., & Li, S. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.134145 · Cited by 29
High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
Kuo, A. M.-S., & Markova, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.898790 · Cited by 30
Meraviglia-Crivelli, D., Villanueva, H., Menon, A. P., Zheleva, A., Moreno, B., Villalba-Esparza, M., & Pastor, F. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.017 · Cited by 28
Rochigneux, P., Lisberg, A. E., Garcia, A. J., Granjeaud, S., Madroszyk, A., Fattori, S., Gonçalvès, A., Devillier, R., Maby, P., Salem, N., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1386 · Cited by 30
Hao, J., Wang, H., Song, L., Li, S., Che, N., Zhang, S., Zhang, H., & Wang, J. (2020) · PubMed Central · Cited by 29
Sanborn, R. E., Hamid, O., de Vries, E. G., Ott, P. A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Cho, D. C., Plummer, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002446 · Cited by 28
p53 mutation and deletion contribute to tumor immune evasion
Liu, S. M., Liu, T., Jiang, J., Guo, H., & Yang, R. L. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1088455 · Cited by 31
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations
Karapetyan, L., Iheagwara, U. K., Olson, A. C., Chmura, S. J., Skinner, H. K., & Luke, J. J. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad118 · Cited by 28
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2
Horton, B. L., D’Souza, A. D., Zagorulya, M., McCreery, C. V., Abhiraman, G. C., Picton, L. K., Sheen, A. M., Agarwal, Y., Momin, N., Wittrup, K. D., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.172728 · Cited by 31
Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
Kalvapudi, S., Vedire, Y., Yendamuri, S., & Barbi, J. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1286104 · Cited by 30
Bjursten, S., Zhao, Z., Remawi, H. A., Studahl, M., Pandita, A., Simrén, J., Zetterberg, H., Lundell, A., Rudin, A., Ny, L., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104955 · Cited by 28
Vallejo, J. J., Singh, H., Larkins, E. A., Drezner, N. L., Ricciuti, B., Mishra-Kalyani, P. S., Tang, S. W., Beaver, J. A., & Awad, M. M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae006 · Cited by 27
Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy
Liu, H., Lu, Y., Zong, J., Zhang, B., Li, X., Qi, H., Yu, T., & Li, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02913-7 · Cited by 34
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 29
García, J., Bañobre, J. R., Afonso-Afonso, F. J., Amenedo, M., Manrique, M. C. A., Campos, B., Casal‐Rubio, J., Núñez, N. F., Pérez, J. L. F., Lázaro-Quintela, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072093 · Cited by 28
Dong, A., Zhao, Y., Li, Z., & Hu, H. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3294 · Cited by 29
Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy
Sznol, M., & Melero, I. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.018 · Cited by 27
The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients
Lasocki, A., Iravani, A., & Galligan, A. (2021) · Clinical Radiology · doi:10.1016/j.crad.2020.12.028 · Cited by 28
Sacdalan, D. B., & Lucero, J. A. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s278089 · Cited by 28
Huff, W. X., Bam, M., Shireman, J. M., Kwon, J. H., Song, L., Newman, S., Cohen‐Gadol, A., Shapiro, S., Jones, T., Fulton, K., et al. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100008 · Cited by 28
Complications following novel therapies for non‐small cell lung cancer
Skribek, M., Rounis, K., Tsakonas, G., & Ekman, S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13445 · Cited by 28
Xiao, Y., He, J., Luo, S., Dong, M., Li, X., Liu, G., Chen, H., Yang, X., & Huang, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.820302 · Cited by 28
Metadata
- Authors
- Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O’Byrne, K. J., Geese, W. J., Bhagavatheeswaran, P., Rabindran, S. K., Kasinathan, R. S., Nathan, F. E., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Universidad Complutense de Madrid (ES)
- From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology–Germans Trias i Pujol Hospital, Badalona (E.C.C.) — all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K....
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 2020-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2976744492
- Cited by
- 2,823
- References
- 26
- Citations by year
- 2026: 183 · 2025: 316 · 2024: 399 · 2023: 448 · 2022: 516 · 2021: 570 · 2020: 368 · 2019: 18
- FWCI
- 154.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- ipilimumab, non-small cell lung cancer, PD-L1 expression, immune checkpoint inhibitors, combination immunotherapy, overall survival, chemotherapy, PD-1, CTLA-4, long-term benefits, PD-L1-negative tumors, stage IV lung cancer, recurrent lung cancer, immune-related adverse events, immune-related pneumonitis
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
